查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370890

生物製造病毒检测和定量市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、技术、按应用、最终用户、地区、竞争细分

Biomanufacturing Viral Detection and Quantifications Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Offering Type, By Technology, By Application, By End-User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球生物製造病毒检测和定量市场价值为 4.8024 亿美元，预计在整个预测期内将呈现强劲增长轨迹，到 2028 年复合年增长率 (CAGR) 为 8.43%，预计价值为2028 年将达到77,173 万。生物製造病毒检测和定量涉及利用生物技术方法和技术来开发用于识别和测量病毒的工具、试剂和系统。该领域融合了生物技术、分子生物学和工程学的原理，建立高效可靠的方法来检测不同样本（包括临床、环境和研究环境）中的病毒。该过程包括大规模生产抗体、探针、引子和酶等基本试剂，这些试剂对于透过聚合酶链反应(PCR)、酶联免疫吸附测定(ELISA) 和各种分子生物学等技术进行病毒检测和定量至关重要化验。该领域还在生产临床实验室和医疗机构用于识别特定病毒感染的诊断试剂盒方面发挥关键作用。这些套件包含进行测试和解释结果所需的所有组件。此外，该领域还有助于开发能够即时或高通量病毒检测的先进感测器平台、生物感测器和微流体设备。这些平台通常包括分子识别元件，例如抗体或核酸探针，以捕获和检测病毒颗粒。用于病毒检测和定量的生物製造涵盖几个关键领域，包括分子诊断、免疫诊断、生物感测器和微流体以及基于细胞的测定。

主要市场驱动因素

病毒性疾病发生率的增加推动市场成长：病毒性疾病盛行率的上升是推动全球生物製造病毒检测和定量市场成长的重要驱动力。世界卫生组织(WHO)估计，目前全球约有一半人口面临感染登革热的风险，每年感染人数为100-4亿。随着病毒性疾病变得更加普遍，早期检测和诊断对于及时的医疗介入变得至关重要。生物製造的病毒检测工具（例如诊断试剂盒和检测方法）为医疗保健专业人员提供了准确、快速的方法来检测患者样本中的病毒。这有助于快速治疗和遏制，有助于减少感染的传播并改善患者的治疗效果。病毒性疾病的增加凸显了强有力的监测和流行病学监测的重要性。生物製造的病毒检测产品透过追踪病毒爆发、了解疾病模式和评估控制措施的有效性，为这些努力做出了贡献。这些资讯对于公共卫生机构、政府和医疗保健提供者做出明智的决策至关重要。

市场概况
预测期 2024-2028
2022 年市场规模 4.8024亿美元
2028 年市场规模 77173万美元
2023-2028 年复合年增长率 8.43%
成长最快的细分市场 耗材
最大的市场 亚太地区

诊断技术的进步推动市场成长：诊断技术的进步在推动全球生物製造病毒检测和定量市场方面发挥关键作用。这些创新提高了病毒检测方法的准确性、速度、灵敏度和可扩展性，从而带来更广泛的应用，并增加了对生物製造的病毒检测和定量产品的需求。新的诊断技术利用创新的分子和免疫学技术，在检测病毒病原体方面实现更高的灵敏度和特异性。生物製造支持生产高度特异性的试剂，例如抗体和探针，这对于精确的病毒检测至关重要。微流体、小型化和感测器技术的进步促进了便携式快速护理点 (POC) 诊断设备的开发。这些设备有助于现场病毒检测，减少样本运输的需要并实现即时决策。生物製造有助于生产用于 POC 测试的组件。现代诊断技术能够在一次检测中同时检测多个病毒标靶。这种多重功能提高了效率、减少了测试时间并节省了样品体积。生物製造支持多重检测和试剂组的创建。数位 PCR 和液滴数位 PCR (ddPCR) 等定量技术可准确测量病毒量。生物製造的标准品和对照品对于建立校准曲线和确保准确定量至关重要。自动化、机器人技术和高通量平台增强了高效处理大量样品的能力。生物製造的试剂和检测组件有助于扩大病毒检测工作流程以达到筛选目的。基于奈米技术的诊断平台提供高灵敏度和快速检测能力。生物製造有助于生产用于病毒检测的奈米感测器和奈米颗粒。下一代定序 (NGS) 技术可以对病毒基因组进行全面分析，从而深入了解病毒多样性、演化和传播。生物製造支持NGS文库的製备和定序试剂的生产。

大流行病的准备和反应推动了市场成长：大流行病的准备和回应极大地推动了全球生物製造病毒检测和定量市场。从以往的大流行和当前疫情中汲取的经验教训强调了强大的病毒检测能力的重要性。 H1N1 流感和 COVID-19 大流行等备受瞩目的流行病强调需要有效的病毒检测工具来识别和控制疫情。这种认识导致对生物製造基础设施的投资增加，以开发和生产诊断试剂、试剂盒和检测方法。在大流行期间，迫切需要快速、准确的诊断测试来识别感染者。生物製造有助于快速开发、验证和生产诊断工具，以便及时筛检和监测，从而实现早期病例识别和遏制。建立紧急应变系统和基础设施对于应对大流行病至关重要。生物製造透过提供病毒抗原、抗体和分子探针等诊断测试组件发挥关键作用。国家、研究机构、诊断製造商和医疗保健提供者之间的合作对于应对大流行至关重要。生物製造商透过提供病毒检测组件和专业知识、促进创新和知识共享做出贡献。大流行加速了研究和开发，以增强诊断技术。生物製造支持新型诊断方法的试剂和材料的生产，提高病毒检测的敏感度、特异性和速度。

主要市场挑战

快速进化的病毒：病毒的快速演化为全球生物製造病毒检测和定量市场带来了重大挑战。病毒突变可以改变检测分析所针对的基因序列。如果突变发生在对检测检测至关重要的区域，则可能会导致假阴性，即儘管存在病毒，但检测仍无法检测到病毒。为了解决新出现的病毒变异，需要不断调整检测方法。突变会影响检测试剂（例如抗体和引子）的结合亲和力，从而可能降低测定的灵敏度或特异性。生物製造商必须不断调整试剂，以保持针对不断进化的病毒株的最佳性能。

复杂样品基质：复杂样品基质对全球生物製造病毒检测和定量市场提出了重大挑战。复杂样本基质是指在临床、环境或其他测试病毒存在的样本中发现的多种物质混合物。这些物质会干扰病毒检测方法并影响结果准确性。复杂样本（例如血液、唾液或环境样本）中的成分可能与检测试剂、抗体或引子相互作用，导致假阳性或阴性。蛋白质、脂质和抑制剂等物质会阻碍检测分子与病毒标靶的结合。复杂的基质可以稀释病毒标靶或降低其浓度，使检测变得更加困难。这会降低检测灵敏度并导致漏检或定量不准确。

高研发成本：高研发（R＆D）成本是全球生物製造病毒检测和定量市场的重大挑战。开发、最佳化和验证

主要市场趋势

新兴传染病的准备：新兴传染病（EID）的准备是全球生物製造病毒检测和定量市场的重要趋势。这一趋势反映出人们越来越认识到需要做好充分准备来快速应对新的和意外的传染病爆发。 EID 准备工作推动了快速、准确的病毒检测测试的发展，这些测试可以在疫情爆发期间快速部署。生物製造商专注于创建能够以高灵敏度和特异性检测新病原体或变异体的诊断检测方法。应对 EID 需要适应性强的製造能力，以快速生产针对新出现病原体的试剂、试剂盒和检测方法。这可能涉及灵活的生产流程和可扩展的製造设施。在 EID 爆发期间，对新病毒检测方法进行严格和快速的验证变得至关重要。生物製造商需要验证并确保针对新病毒株的检测性能，以保持可靠性。生物製造公司、研究机构、公共卫生机构和政府之间的合作加速了有效病毒检测解决方案的开发和推广。在 EID 爆发期间，监管机构可能会加快新病毒检测产品的审批流程，以促进快速部署。生物製造商需要与监管机构密切合作。生物製造的病毒检测产品在监测新出现的病原体传播和影响的全球监测工作中发挥关键作用。早期发现和监测对于有效应对疫情至关重要。这些工具对于评估 EID 爆发期间的疫苗功效至关重要，有助于追踪病原体流行情况和监测疫苗接种活动的影响。

细分市场洞察

产品类型洞察： 2022 年，消耗品细分市场在生物製造病毒检测和定量市场中占据主导地位，预计在未来几年将继续扩张。耗材是病毒检测工作流程的重要组成部分，需要根据使用情况定期补充。这会导致重复购买，为生物製造公司提供稳定的收入来源。病毒检测和定量分析在临床实验室、研究机构和公共卫生机构中常规进行，导致对检测的持续需求。不同的病毒标靶、样本类型和检测格式需要定製或专门的耗材，为生物製造商提供一系列产品来满足特定的测试要求。高品质的耗材对于准确可靠的病毒检测至关重要，需要严格的品质控制和验证以确保一致的性能。预计 2023 年至 2030 年该细分市场将经历最高的复合年增长率 (CAGR)。

技术洞察： 2022年，PCR（聚合酶炼式反应）技术领域主导了生物製造病毒检测和定量市场，预计在可预见的未来将继续成长。 PCR 以其高灵敏度和特异性而闻名，使其成为准确检测低病毒量的理想选择，尤其是在疫情爆发的早期阶段。 PCR 适用于病毒遗传物质的定性（存在/不存在）和定量（病毒量）分析。定量资料有助于疾病监测、评估治疗效果和研究应用。 PCR 可以针对特定的病毒基因或区域，因此可以针对各种病毒目标进行客製化。这种多功能性使其适合检测多种病毒病原体。即时 PCR (qPCR) 等变异体通常可在数小时内提供快速结果，这对于快速临床决策和疫情应对至关重要。多重 PCR 能够在一次反应中同时检测多个病毒标靶，从而提高效率并节省样本量，这对于高效筛检和监测至关重要。跨实验室的标准化 PCR 检测可确保结果的一致性和可比性，这对于准确的疾病监测和研究合作至关重要。 PCR 技术已经成熟并在临床环境中被广泛接受，许多检测方法已获得监管部门批准用于诊断。

应用洞察：到 2022 年，血液和血液製品製造领域在生物製造病毒检测和定量市场中占据主导地位，预计将继续其成长轨迹。血液和血液製品是医疗保健系统不可或缺的一部分，确保其安全免受病毒污染至关重要。病毒检测用于筛检捐血者是否存在感染性病毒，例如 HIV、乙型和丙型肝炎以及人类 T 细胞淋巴细胞病毒 (HTLV)。这对于防止病毒透过输血传播至关重要。血浆用于生产各种血浆衍生产品，包括凝血因子和免疫球蛋白，这强调了病毒检测在确保无污染血浆捐赠方面的重要性。

最终用户见解： 2022 年，临床实验室和医院在生物製造病毒检测和定量市场中占据主导地位，预计将继续扩张。临床实验室和医院是用于诊断目的的病毒检测和定量技术的主要使用者。他们进行常规病毒感染检测，以支持患者护理和治疗决策。生物製药公司在各个药物开发阶段采用病毒检测方法，包括研究、品质控制以及疫苗和单株抗体等生物製品的生产。学术和研究机构利用病毒检测和定量技术进行基础研究、流行病学研究和新诊断方法的开发。

区域见解：亚太地区成为全球生物製造病毒检测和定量市场的领导者。亚太地区拥有世界上最大且成长最快的人口，对医疗保健服务的需求不断增长，包括生物製造病毒检测和定量。该地区爱滋病毒、B型肝炎和丙型肝炎等病毒性疾病的盛行率也很高，因此需要病毒检测和定量测试来诊断和管理这些疾病。

结论：全球生物製造病毒检测和定量市场呈现出巨大的成长潜力，其驱动因素包括病毒性疾病发病率的增加、诊断技术的进步以及大流行防范和应对的必要性。需要应对快速进化的病毒、复杂的样本基质以及高昂的研发成本等挑战。主要市场趋势包括强调新兴传染病的防范。产品类型、技术、应用和最终用户等细分市场呈现不同的动态，其中耗材、PCR 技术、血液和血液製品製造以及临床实验室和医院发挥关键作用。此外，在人口规模和医疗保健需求的推动下，亚太地区成为市场的领导者。这些见解强调了全球生物製造病毒检测和量化领域的重大机会和挑战。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球生物製造病毒检测与定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（消耗品、仪器、服务）
    • 依技术（PCR、ELISA、流式细胞仪、噬菌斑测定等）
    • 按应用（血液和血液製品製造、疫苗和疗法製造、细胞和基因治疗产品製造、干细胞产品製造、组织和组织产品製造）
    • 按最终用户（生命科学公司、测试实验室、CRO 和 CDMO）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美生物製造病毒检测与定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲生物製造病毒检测与定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区生物製造病毒检测与定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲生物製造病毒检测与定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲生物製造病毒检测和定量市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非生物製造病毒检测和定量
    • 沙乌地阿拉伯生物製造病毒检测和定量
    • 阿联酋生物製造病毒检测与定量

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Danaher Corporation
    • Merck KGaA
    • New England Biolabs
    • TAKARA HOLDINGS INC.
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Sartorius AG
    • Charles River Laboratories
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.

第 16 章：策略建议

简介目录
Product Code: 15881

The Global Biomanufacturing Viral Detection and Quantifications Market recorded a value of USD 480.24 Million in 2022, with a projected strong growth trajectory throughout the forecast period, showcasing a Compound Annual Growth Rate (CAGR) of 8.43% until 2028 and expected to be valued at USD 771.73 Million in 2028. Biomanufacturing Viral Detection and Quantifications involve the utilization of biotechnological methods and techniques to develop tools, reagents, and systems used in identifying and measuring viruses. This field amalgamates principles from biotechnology, molecular biology, and engineering to establish efficient and reliable methods for detecting viruses in diverse samples, including clinical, environmental, and research settings. The process encompasses large-scale production of essential reagents such as antibodies, probes, primers, and enzymes, vital for virus detection and quantification through techniques like Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), and various molecular biology assays. The domain also plays a pivotal role in producing diagnostic kits used in clinical laboratories and healthcare facilities for identifying specific viral infections. These kits encompass all the necessary components to conduct tests and interpret results. Furthermore, the arena contributes to the development of advanced sensor platforms, biosensors, and microfluidic devices capable of real-time or high-throughput virus detection. These platforms often include molecular recognition elements such as antibodies or nucleic acid probes to capture and detect viral particles. Biomanufacturing for viral detection and quantification encompasses several key areas including Molecular Diagnostics, Immunodiagnostics, Biosensors and Microfluidics, and Cell-Based Assays.

Key Market Drivers

Increasing Incidence of Viral Diseases Drive the Market Growth: The rising prevalence of viral diseases is a significant driver propelling the growth of the global biomanufacturing viral detection and quantification market. The World Health Organization (WHO) estimates that approximately half of the global population is currently at risk of contracting dengue, with an annual infection rate of 100-400 million. As viral diseases become more widespread, early detection and diagnosis become crucial for timely medical interventions. Bio manufactured viral detection tools, such as diagnostic kits and assays, provide healthcare professionals with accurate and rapid means to detect viruses in patient samples. This facilitates swift treatment and containment, which aids in reducing the spread of infections and enhancing patient outcomes. The increase in viral diseases underscores the importance of robust surveillance and epidemiological monitoring. Bio manufactured viral detection products contribute to these efforts by enabling the tracking of viral outbreaks, understanding disease patterns, and evaluating control measures' effectiveness. This information is vital for informed decision-making by public health agencies, governments, and healthcare providers.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 480.24 Million
Market Size 2028USD 771.73 Million
CAGR 2023-20288.43%
Fastest Growing SegmentConsumables
Largest MarketAsia Pacific

Advancement In Diagnostic Technology Propels the Market Growth: Technological advancements in diagnostics play a pivotal role in driving the global biomanufacturing viral detection and quantification market. These innovations enhance the accuracy, speed, sensitivity, and scalability of viral detection methods, leading to broader applications and increased demand for bio manufactured viral detection and quantification products. New diagnostic technologies leverage innovative molecular and immunological techniques to achieve higher sensitivity and specificity in detecting viral pathogens. Biomanufacturing supports the production of highly specific reagents, such as antibodies and probes, essential for precise viral detection. Microfluidics, miniaturization, and sensor technologies advancements enable the development of portable and rapid Point-of-Care (POC) diagnostic devices. These devices facilitate on-site virus detection, reducing the need for sample transportation and enabling real-time decision-making. Biomanufacturing contributes to the production of components for POC tests. Modern diagnostic technologies enable the simultaneous detection of multiple viral targets in a single assay. This multiplexing capability improves efficiency, reduces testing time, and conserves sample volume. Biomanufacturing supports the creation of multiplex assays and reagent panels. Quantitative techniques like Digital PCR and droplet digital PCR (ddPCR) provide accurate measurements of viral load. Bio manufactured standards and controls are pivotal for establishing calibration curves and ensuring accurate quantification. Automation, robotics, and high-throughput platforms enhance the ability to process a large number of samples efficiently. Bio manufactured reagents and assay components facilitate scaling up viral detection workflows for screening purposes. Nanotechnology-based diagnostic platforms offer high sensitivity and rapid detection capabilities. Biomanufacturing contributes to the production of nano sensors and nanoparticles used in viral detection. Next-Generation Sequencing (NGS) technologies enable comprehensive analysis of viral genomes, providing insights into viral diversity, evolution, and transmission. Biomanufacturing supports the preparation of NGS libraries and the production of sequencing reagents.

The Pandemic Preparedness and Response Drives the Market Growth: Pandemic preparedness and response significantly drive the global biomanufacturing viral detection and quantification market. Lessons learned from previous pandemics and ongoing outbreaks emphasize the importance of robust viral detection capabilities. High-profile pandemics such as H1N1 influenza and the COVID-19 pandemic underscore the need for effective viral detection tools to identify and control outbreaks. This awareness results in increased investment in biomanufacturing infrastructure to develop and produce diagnostic reagents, kits, and assays. During pandemics, rapid and accurate diagnostic tests are urgently required to identify infected individuals. Biomanufacturing facilitates the swift development, validation, and production of diagnostic tools for timely screening and surveillance, enabling early case identification and containment. The establishment of emergency response systems and infrastructure is crucial for pandemic preparedness. Biomanufacturing plays a pivotal role by supplying components for diagnostic tests such as viral antigens, antibodies, and molecular probes. Collaborative efforts between countries, research institutions, diagnostic manufacturers, and healthcare providers are essential to pandemic response. Biomanufacturers contribute by providing viral detection components and expertise, fostering innovation and knowledge sharing. Pandemics accelerate research and development to enhance diagnostic technologies. Biomanufacturing supports the production of reagents and materials for novel diagnostic methods, enhancing the sensitivity, specificity, and speed of viral detection.

Key Market Challenges

Rapidly Evolving Viruses: The swift evolution of viruses presents significant challenges to the global biomanufacturing viral detection and quantification market. Viral mutations can alter the genetic sequences targeted by detection assays. If a mutation occurs in a region crucial for assay detection, it can result in false negatives, where the assay fails to detect the virus despite its presence. Continuous adaptation of assays is necessary to account for emerging viral variants. Mutations can affect the binding affinity of detection reagents, such as antibodies and primers, potentially reducing assay sensitivity or specificity. Biomanufacturers must continuously adjust reagents to maintain optimal performance against evolving viral strains.

Complex Sample Matrices: Complex sample matrices pose a significant challenge in the global biomanufacturing viral detection and quantification market. Complex sample matrices refer to the diverse mixture of substances found in clinical, environmental, or other samples tested for viral presence. These substances can interfere with viral detection methods and impact result accuracy. Components in complex samples, such as blood, saliva, or environmental samples, can interact with detection reagents, antibodies, or primers, leading to false positives or negatives. Substances like proteins, lipids, and inhibitors can hinder the binding of detection molecules to viral targets. Complex matrices can dilute viral targets or lower their concentration, making detection more difficult. This can reduce assay sensitivity and result in missed infections or inaccurate quantification.

High Research and Development Costs: High research and development (R&D) costs represent a significant challenge in the global biomanufacturing viral detection and quantification market. Developing, optimizing, and validating

new viral detection methods and products can incur substantial expenses. The costs can strain the financial resources of biomanufacturers, particularly smaller companies and startups. Limited funds may hinder their ability to invest in innovative research and product development. High R&D costs can act as entry barriers for new market players, limiting competition and potentially slowing innovation. This can lead to a lack of diverse and cutting-edge viral detection solutions. Lengthy and expensive R&D processes can delay the introduction of new products to the market. Delays could impact the availability of timely and up-to-date viral detection tools during outbreaks or emerging viral threats. Rigorous validation and testing of new viral detection methods are essential for accuracy and reliability, contributing to higher R&D costs. This is particularly critical in the context of complex sample matrices and rapidly evolving viruses. Developing high-quality reagents and materials suitable for viral detection methods requires investments in research, manufacturing, and quality control.

Key Market Trends

Emerging Infectious Diseases Preparedness: Preparedness for emerging infectious diseases (EIDs) is a significant trend in the global biomanufacturing viral detection and quantification market. This trend reflects the growing recognition of the need to be well-equipped to rapidly respond to new and unexpected infectious disease outbreaks. EID preparedness drives the development of rapid and accurate viral detection tests that can be quickly deployed during outbreaks. Biomanufacturers focus on creating diagnostic assays that can detect new pathogens or variants with high sensitivity and specificity. Responding to EIDs requires adaptable manufacturing capabilities to swiftly produce reagents, kits, and assays for emerging pathogens. This may involve flexible production processes and scalable manufacturing facilities. Rigorous and expedited validation of new viral detection assays becomes crucial during EID outbreaks. Biomanufacturers need to validate and ensure assay performance against new viral strains to maintain reliability. Collaboration between biomanufacturing companies, research institutions, public health agencies, and governments accelerates the development and distribution of effective viral detection solutions. Regulatory authorities may expedite the approval process for new viral detection products during EID outbreaks to facilitate rapid deployment. Biomanufacturers need to closely collaborate with regulatory bodies. Biomanufactured viral detection products play a critical role in global surveillance efforts to monitor emerging pathogen spread and impact. Early detection and monitoring are essential for effective outbreak response. These tools are vital for assessing vaccine efficacy during EID outbreaks, aiding in tracking pathogen prevalence and monitoring vaccination campaign impact.

Segmental Insights

Offering Type Insights: In 2022, the Consumables Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is expected to continue its expansion in the years ahead. Consumables are essential components of viral detection workflows, requiring regular replenishment due to usage. This results in repeat purchases, providing a steady revenue stream for biomanufacturing companies. Viral detection and quantification assays are performed routinely in clinical laboratories, research institutions, and public health agencies, leading to consistent demand for testing. Different viral targets, sample types, and assay formats necessitate customized or specialized consumables, offering biomanufacturers an array of products to meet specific testing requirements. High-quality consumables are crucial for accurate and reliable viral detection, subjected to rigorous quality control and validation to ensure consistent performance. The segment is projected to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Technology Insights: In 2022, the PCR (Polymerase Chain Reaction) Technology Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is anticipated to continue its growth in the foreseeable future. PCR is renowned for its high sensitivity and specificity, making it ideal for accurately detecting even low viral loads, especially in the early stages of an outbreak. PCR is applicable for both qualitative (presence/absence) and quantitative (viral load) analysis of viral genetic material. The quantitative data aids in disease monitoring, assessing treatment efficacy, and research applications. PCR can target specific viral genes or regions, allowing customization for various viral targets. This versatility makes it suitable for detecting a wide array of viral pathogens. Variants such as Real-Time PCR (qPCR) provide rapid results, often within hours, essential for swift clinical decision-making and outbreak response. Multiplex PCR enables simultaneous detection of multiple viral targets in a single reaction, enhancing efficiency and conserving sample volume, crucial for efficient screening and surveillance. Standardized PCR assays across laboratories ensure consistent and comparable results, critical for accurate disease monitoring and research collaboration. PCR technology is well-established and widely accepted in clinical settings, with numerous assays receiving regulatory approvals for diagnostic use.

Application Insights: In 2022, the Blood and Blood Products Manufacturing Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is projected to continue its growth trajectory. Blood and blood products are integral components of healthcare systems, and ensuring their safety from viral contamination is of paramount importance. Viral detection assays are used to screen blood donations for infectious viruses like HIV, hepatitis B and C, and human T-cell lymphotropic virus (HTLV). This is crucial in preventing virus transmission through blood transfusions. Blood plasma is utilized for producing various plasma-derived products, including clotting factors and immunoglobulins, underscoring the importance of viral detection in ensuring contamination-free plasma donations.

End-User Insights: In 2022, Clinical Laboratories and Hospitals dominated the Biomanufacturing Viral Detection and Quantifications market and are predicted to continue their expansion. Clinical laboratories and hospitals are primary users of viral detection and quantification technologies for diagnostic purposes. They conduct routine viral infection testing to support patient care and treatment decisions. Biopharmaceutical companies employ viral detection methods across various drug development stages, including research, quality control, and production of biologics like vaccines and monoclonal antibodies. Academic and research institutions leverage viral detection and quantification technologies for basic research, epidemiological studies, and new diagnostic method development.

Regional Insights: The Asia-Pacific region emerges as a leader in the Global Biomanufacturing Viral Detection and Quantifications Market. With the world's largest and fastest-growing population, the Asia-Pacific region witnesses increasing demand for healthcare services, including biomanufacturing viral detection and quantification. The region also experiences a high prevalence of viral diseases such as HIV, hepatitis B, and hepatitis C, driving the need for viral detection and quantification tests to diagnose and manage these diseases.

In Conclusion: The Global Biomanufacturing Viral Detection and Quantifications Market presents significant growth potential driven by the increasing incidence of viral diseases, advancements in diagnostic technology, and the imperative for pandemic preparedness and response. Challenges such as rapidly evolving viruses, complex sample matrices, and high research and development costs need to be navigated. Key market trends include the emphasis on emerging infectious diseases preparedness. Segments like offering types, technology, applications, and end-users showcase varied dynamics, with consumables, PCR technology, blood and blood product manufacturing, and clinical laboratories and hospitals playing pivotal roles. Moreover, the Asia-Pacific region emerges as a frontrunner in the market, driven by its population size and healthcare demands. These insights underscore the significant opportunities and challenges within the global biomanufacturing viral detection and quantification landscape.

Key Market Players

  • Danaher Corporation
  • Merck KGaA
  • New England Biolabs
  • TAKARA HOLDINGS INC.
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Sartorius AG
  • Charles River Laboratories
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc

Report Scope:

In this report, the Global Biomanufacturing Viral Detection and Quantifications Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biomanufacturing Viral Detection and Quantifications Market, By Offering Type:

  • Consumables
  • Instruments
  • Services

Biomanufacturing Viral Detection and Quantifications Market, By Technology:

  • PCR
  • ELISA
  • Flow Cytometry
  • Plaque Assay
  • Others

Biomanufacturing Viral Detection and Quantifications Market, By Application:

  • Blood and Blood Products Manufacturing
  • Vaccines and Therapeutics Manufacturing
  • Cellular and Gene Therapy Products Manufacturing
  • Stem Cell Products Manufacturing
  • Tissue and Tissue Products Manufacturing

Biomanufacturing Viral Detection and Quantifications Market, By End User:

  • Life Science Companies
  • Testing Laboratories
  • CROs and CDMOs

Global Biomanufacturing Viral Detection and Quantifications Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Biomanufacturing Viral Detection and Quantifications Market.

Available Customizations:

  • Global Biomanufacturing Viral Detection and Quantifications Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering Type (Consumables, instruments, Services)
    • 5.2.2. By Technology (PCR, ELISA, FLOW Cytometry, Plaque Assay, Others)
    • 5.2.3. By Application (Blood and Blood Products Manufacturing, Vaccine and Therapeutics Manufacturing, Cellular and Gene Therapy Products Manufacturing, Stem Cell Products Manufacturing, Tissue and tissue Products Manufacturing)
    • 5.2.4. By End-User (Life Science Companies, testing Laboratories, CROs and CDMOs)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-User
    • 6.3.2. Mexico Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-User
    • 6.3.3. Canada Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-User

7. Europe Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-User
    • 7.3.2. Germany Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-User

8. Asia-Pacific Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-User
    • 8.3.3. South Korea Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-User
    • 8.3.4. Japan Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-User

9. South America Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-User
    • 9.3.2. Argentina Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-User
    • 9.3.3. Colombia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-User

10. Middle East and Africa Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-User
    • 10.3.2. Saudi Arabia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-User
    • 10.3.3. UAE Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Danaher Corporation
    • 15.6.2. Merck KGaA
    • 15.6.3. New England Biolabs
    • 15.6.4. TAKARA HOLDINGS INC.
    • 15.6.5. Thermo Fisher Scientific Inc.
    • 15.6.6. Agilent Technologies, Inc.
    • 15.6.7. Sartorius AG
    • 15.6.8. Charles River Laboratories
    • 15.6.9. Bio-Rad Laboratories, Inc.
    • 15.6.10. PerkinElmer, Inc.

16. Strategic Recommendations